Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
33 hedge funds and large institutions have $150M invested in Sierra Oncology, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
23% more capital invested
Capital invested by funds: $122M → $150M (+$27.9M)
6% more funds holding
Funds holding: 31 → 33 (+2)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$12.5M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$7.13M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.2M |
| 5 |
PVI
Pura Vida Investments
New York
|
+$924K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$3.17M |
| 2 |
6CM
683 Capital Management
New York
|
-$2.25M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$1.75M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$208K |
| 5 |
TI
Telemetry Investments
New York
|
-$24.8K |
SRRA Hedge Fund Activity: Q1 2021 in Review
33 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q1 2021, worth a combined $150M — up 23% from $122M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SRRA positions and 2 closed out — a net gain of 2 holders — while 11 added to existing stakes and 6 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $12.5M. The largest seller was Caxton Corporation, cutting an estimated $3.17M.
- 33 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q1 2021, up from 31 in Q4 2020.
- Funds reported $150M of Sierra Oncology, Inc. Common Stock stock for Q1 2021, up 23% quarter-over-quarter.
- 4 funds opened new Sierra Oncology, Inc. Common Stock positions in Q1 2021 and 2 closed out, a net change of +2 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q1 2021 was Adage Capital Partners, an estimated $12.5M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q1 2021 was Caxton Corporation, an estimated $3.17M sold.
Based on aggregated 13F filings for Q1 2021.